Late-Breaking Science Announced for TVT Connect

The Cardiovascular Research Foundation (CRF) announced that TVT Connect will feature eight studies as Late-Breaking Clinical Science. They will be presented during episodes moderated by the editors of Circulation: Cardiovascular Interventions and JACC: Cardiovascular Interventions. Each late-breaking science episode will host a live wrap-up and Q&A session afterwards.

Read more

TCT 2020 Is Now a Virtual Event: TCT Connect

The Cardiovascular Research Foundation (CRF) has announced that Transcatheter Cardiovascular Therapeutics (TCT) 2020 will now take place as a virtual event called TCT Connect. The event will take place online October 14-18, 2020 and feature live case-based transmissions from around the globe, late-breaking clinical trials and science, virtual training, and countless opportunities to learn and engage with the brightest minds in interventional cardiovascular medicine.

Read more

PCR and CRF Announce Partners in Learning Virtual Sessions

PCR and CRF are pleased to announce the creation of virtual Partners in Learning sessions that will be broadcast during the PCR e-Course (June 25-27, 2020) and CRF’s TVT Connect meeting (June 18-28, 2020). The sessions, which will cover coronary artery disease in TAVI patients and TAVI in low risk patients, are part of a collaborative educational series from the two groups.

Read more

Introducing TVT Connect

The Cardiovascular Research Foundation (CRF) has announced that TVT Connect, the Structural Heart Summit, will take place online June 18-28, 2020. TVT Connect features expertly developed series, late-breaking clinical science, challenging cases, industry-sponsored sessions, and connection to a community of thought leaders from across the globe.

Read more

New Research Supports Initial Conservative Management of Stable Coronary Artery Disease

New study results confirm that guideline-directed medical therapy is as effective as more invasive procedures at preventing death, stroke, and heart attack in patients with stable coronary artery disease (CAD).

The study results suggest that guideline-directed medical therapy should be the initial treatment strategy for patients with stable CAD.

The study results validate the evidence-based, guideline-directed, conservative treatment approach that the cardiovascular specialists at Nuvance Health have always used to treat CAD.

Read more

PCR and TCT Announce the Creation of a New Educational Program: Partners in Learning

PCR and TCT are proud to announce the creation of a new educational program: “Partners in Learning.” The first of its kind will focus on TAVI practitioners, taking place on 21-22 March 2020 in Sao Paulo, Brazil. It is the first ever stand-alone collaboration between TCT, PCR, and a regional core team of leading practitioners.

Read more

Treating Pulmonary Embolism: How Safe and Effective Are New Devices?

A new scientific statement from the American Heart Association identifies the risks and benefits of using novel interventional devices compared to anticoagulation alone to treat patients with pulmonary embolism.

Read more

New TAVR System Safe and Effective for High-Risk Surgical Patients with Severe Aortic Stenosis

The Portico IDE study found that 30-day safety and one-year effectiveness outcomes of a novel self-expanding transcatheter aortic valve replacement (TAVR) system for patients with severe aortic stenosis (AS) at high or extreme-risk for surgery was noninferior to contemporary FDA-approved TAVR systems available in the United States.

Read more

Three-Year COAPT Data Demonstrates Continued Safety and Effectiveness in Patients with Heart Failure and Secondary Mitral Regurgitation

The three-year results from the COAPT trial demonstrated that reducing severe secondary mitral regurgitation (SMR) with the MitraClip device safely improves prognosis in selected heart failure (HF) patients. In addition, those patients that crossed over and received the MitraClip after 24 months showed the same benefits as those who received the device at the beginning of the study. Two-year data were presented at TCT 2018 and published in the New England Journal of Medicine.

Read more